Li Jing1, Yanyan Qiu2, Yanan Zhang3, Jun-Xu Li4. 1. Department of Pharmacology and Toxicology, University at Buffalo, Buffalo, NY, USA; Department of Physiology and Pathophysiology, Tianjin Medical University, Tianjin, China. 2. Department of Pharmacology and Toxicology, University at Buffalo, Buffalo, NY, USA. 3. Research Triangle Institute, Research Triangle Park, NC, USA. 4. Department of Pharmacology and Toxicology, University at Buffalo, Buffalo, NY, USA. Electronic address: junxuli@buffalo.edu.
Abstract
BACKGROUND: Cannabinoid CB1 receptors play an essential role in drug addiction. Given the side effect profiles of orthosteric CB1 antagonism, new strategies have been attempted to modulate this target, such as CB1 receptor allosteric modulation. However, the effect of CB1 allosteric modulation in drug addiction is unknown. The present study examined the effects of the CB1 receptor allosteric modulator ORG27569 on the reinstatement of cocaine- and methamphetamine-seeking behavior in rats. METHODS: Rats were trained to self-administer 0.75 mg/kg cocaine or 0.05 mg/kg methamphetamine in 2-h daily sessions for 14 days which was followed by 7 days of extinction sessions in which rats responded on the levers with no programmed consequences. On reinstatement test sessions, rats were administered ORG27569 (1.0, 3.2, 5.6 mg/kg, i.p.) or SR141716A (3.2 mg/kg, i.p.) 10 min prior to re-exposure to cocaine- or methamphetamine-paired cues or a priming injection of cocaine (10mg/kg, i.p.) or methamphetamine (1mg/kg, i.p.). RESULTS: Both cues and a priming injection of cocaine or methamphetamine significantly reinstated the extinguished active lever responding. Pretreatment with ORG27569 resulted in a dose-related attenuation of both cue- and drug-induced reinstatement of cocaine- and methamphetamine-seeking behavior. SR141716A also exhibited similar inhibitory action on reinstatement of drug-seeking behavior. CONCLUSION: Negative allosteric modulation of CB1 receptors can produce similar functional antagonism as orthosteric CB1 receptor antagonists on reinstatement of drug-seeking behavior. Thus, ORG27569 or other negative allosteric modulators deserve further study as potentially effective pharmacotherapy for drug addiction.
BACKGROUND:CannabinoidCB1 receptors play an essential role in drug addiction. Given the side effect profiles of orthosteric CB1 antagonism, new strategies have been attempted to modulate this target, such as CB1 receptor allosteric modulation. However, the effect of CB1 allosteric modulation in drug addiction is unknown. The present study examined the effects of the CB1 receptor allosteric modulator ORG27569 on the reinstatement of cocaine- and methamphetamine-seeking behavior in rats. METHODS:Rats were trained to self-administer 0.75 mg/kg cocaine or 0.05 mg/kg methamphetamine in 2-h daily sessions for 14 days which was followed by 7 days of extinction sessions in which rats responded on the levers with no programmed consequences. On reinstatement test sessions, rats were administered ORG27569 (1.0, 3.2, 5.6 mg/kg, i.p.) or SR141716A (3.2 mg/kg, i.p.) 10 min prior to re-exposure to cocaine- or methamphetamine-paired cues or a priming injection of cocaine (10mg/kg, i.p.) or methamphetamine (1mg/kg, i.p.). RESULTS: Both cues and a priming injection of cocaine or methamphetamine significantly reinstated the extinguished active lever responding. Pretreatment with ORG27569 resulted in a dose-related attenuation of both cue- and drug-induced reinstatement of cocaine- and methamphetamine-seeking behavior. SR141716A also exhibited similar inhibitory action on reinstatement of drug-seeking behavior. CONCLUSION: Negative allosteric modulation of CB1 receptors can produce similar functional antagonism as orthosteric CB1 receptor antagonists on reinstatement of drug-seeking behavior. Thus, ORG27569 or other negative allosteric modulators deserve further study as potentially effective pharmacotherapy for drug addiction.
Authors: Martin R Price; Gemma L Baillie; Adèle Thomas; Lesley A Stevenson; Morag Easson; Richard Goodwin; Adèle McLean; Lorraine McIntosh; Gillian Goodwin; Glenn Walker; Paul Westwood; Julia Marrs; Fiona Thomson; Phillip Cowley; Arthur Christopoulos; Roger G Pertwee; Ruth A Ross Journal: Mol Pharmacol Date: 2005-08-19 Impact factor: 4.436
Authors: Guadalupe Soria; Victoria Mendizábal; Clara Touriño; Patricia Robledo; Catherine Ledent; Marc Parmentier; Rafael Maldonado; Olga Valverde Journal: Neuropsychopharmacology Date: 2005-09 Impact factor: 7.853
Authors: Thomas F Gamage; Charlotte E Farquhar; Timothy W Lefever; Brian F Thomas; Thuy Nguyen; Yanan Zhang; Jenny L Wiley Journal: Neuropharmacology Date: 2017-08-10 Impact factor: 5.250
Authors: Thuy Nguyen; Jun-Xu Li; Brian F Thomas; Jenny L Wiley; Terry P Kenakin; Yanan Zhang Journal: Med Res Rev Date: 2016-11-23 Impact factor: 12.944
Authors: Samuel D Banister; Kaavya Krishna Kumar; Vineet Kumar; Brian K Kobilka; Sanjay V Malhotra Journal: Medchemcomm Date: 2019-03-18 Impact factor: 3.597
Authors: Bogna M Ignatowska-Jankowska; Gemma L Baillie; Steven Kinsey; Molly Crowe; Sudeshna Ghosh; Robert A Owens; Imad M Damaj; Justin Poklis; Jenny L Wiley; Matteo Zanda; Chiara Zanato; Iain R Greig; Aron H Lichtman; Ruth A Ross Journal: Neuropsychopharmacology Date: 2015-06-08 Impact factor: 7.853
Authors: Thuy Nguyen; Nadezhda German; Ann M Decker; Jun-Xu Li; Jenny L Wiley; Brian F Thomas; Terry P Kenakin; Yanan Zhang Journal: Bioorg Med Chem Date: 2015-03-07 Impact factor: 3.641